Elicio Therapeutics Inc./$ELTX
1D1W1MYTD1Y5YMAX
About Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
- Ticker
- $ELTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 33
- Headquarters
- Boston, United States
- Website
- elicio.com
ELTX Metrics
BasicAdvanced
$82M
-
-$2.17
1.88
-
Price and volume
Market cap
$82M
Beta
1.88
52-week high
$16.00
52-week low
$2.66
Average daily volume
501K
Financial strength
Current ratio
2.77
Quick ratio
2.552
Long term debt to equity
164.735
Total debt to equity
178.254
Interest coverage (TTM)
-24.00%
Profitability
EBITDA (TTM)
-37.738
Management effectiveness
Return on assets (TTM)
-77.88%
Return on equity (TTM)
-774.56%
Valuation
Price to book
8.58
Price to tangible book (TTM)
8.58
Price to free cash flow (TTM)
-1.437
Free cash flow yield (TTM)
-69.60%
Free cash flow per share (TTM)
-2.165
Growth
Earnings per share change (TTM)
-44.04%
3-year earnings per share growth (CAGR)
-58.52%
ELTX News
AllArticlesVideos
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Business Wire2 months ago
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Benzinga2 months ago
Elicio Therapeutics Pancreatic Cancer Study Disappoints
Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.